What is the difference between NR and NMN?

NR is one step further back in the pathway. Cells phosphorylate NR to NMN, then convert NMN to NAD+.

Why not just supply NAD+?

It is over twice NR's mass, carries two negative charges, and does not cross membranes. Precursors do.

NAD+

NAD+ Precursors: Nicotinamide Riboside and NMN

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-234 cited sources

Nicotinamide riboside is 255.25 Da and nicotinamide mononucleotide is 334.22 Da. Both are precursors cells convert into NAD+ through the salvage pathway, and both are small enough to be taken up in ways NAD+ itself is not — which is why almost all human trial data uses them.

Key facts

NR: 255.25 Da, C11H15N2O5+, CID 439924
NMN: 334.22 Da, C11H15N2O8P, CID 14180
NAD+: 663.4 Da — over twice NR
Route: Salvage pathway
NR to NMN: Phosphorylation by NRK enzymes
NMN to NAD+: Adenylylation by NMNAT

The salvage pathway

Cells do not usually build NAD+ from scratch. They recycle it from nicotinamide-containing fragments — the products of NAD+ consumption by sirtuins, PARPs and CD38. Supplying NR or NMN feeds that existing recycling route rather than establishing a new one, which is why both work as precursors at all.

How each enters

NR is phosphorylated by nicotinamide riboside kinases to make NMN. NMN is then adenylylated by NMNAT enzymes to make NAD+. So NR is one step further back than NMN, and NMN is the immediate precursor. NR crosses into the cell as the smaller uncharged-at-that-position molecule; NMN's route has been the subject of more debate, since it carries a phosphate.

Research material referenced

NAD+ 500mg — third-party HPLC tested

View — £49.99

Why size and charge decide this

NR at 255.25 Da is under 40% of NAD+'s mass and lacks the pyrophosphate bridge entirely. NMN at 334.22 Da carries one phosphate rather than two. Both are substantially less encumbered than the finished coenzyme, and the pattern is consistent: the further back down the pathway, the easier the molecule is to deliver.

What the trials used

NADPARK, published in Cell Metabolism in 2022, was a randomised phase I trial of nicotinamide riboside in Parkinson's disease. Orr and colleagues ran a randomised placebo-controlled trial of NR in older adults, published in GeroScience in 2024. Yoshino and colleagues published NMN work in Science in 2021. The precursor choice is uniform across the serious literature.

Which is better

Not settled, and the question is more contested than either side's marketing suggests. NR has more published randomised trial data; NMN has the higher-profile single result in Yoshino's Science paper. Both raise measured NAD+-related markers in at least some tissues. Neither has demonstrated the downstream clinical outcomes the field is ultimately interested in.

Quick reference

	MW	Phosphates	Steps to NAD+
Nicotinamide riboside	255.25 Da	None	Two
Nicotinamide mononucleotide	334.22 Da	One	One
NAD+	663.4 Da	Two	—

Extended research context

The NAD+ deep dive

Deep dive: the compound in this catalogue that is not a peptide

NAD+ contains no amino acids and no peptide bonds. It is a dinucleotide - a nicotinamide nucleotide and an adenine nucleotide joined through a pyrophosphate bridge - which is the structural grammar of ATP and of RNA, not of a protein. It sits in a peptide catalogue because it reaches the same buyers, not because it belongs there. Saying so matters practically rather than pedantically: essentially all of the general handling guidance on this site is written for peptides and is the wrong guidance here. There is no sequence to verify, so purity by amino acid analysis is meaningless. There are no deletion sequences, because there is no stepwise coupling to produce them. Net peptide content, the figure that decides how much material a lyophilised peptide vial actually contains, has no analogue at all. Even the instruction that does carry over - dry, cold, dark - protects different chemistry, guarding glycosidic and pyrophosphate bonds rather than peptide bonds and methionine residues.

Deep dive: why the finished molecule is the least deliverable of the three

NAD+ carries two negatively charged phosphates and weighs 663.4 Da, and neither property is compatible with crossing a lipid bilayer. Extracellular NAD+ is also actively consumed: CD38 is an ectoenzyme with its active site facing outward, and Covarrubias and colleagues reported in Nature Metabolism in 2020 that senescent cells drive tissue NAD+ decline specifically by raising CD38 activity. Put those together and administered NAD+ is a molecule that cannot get in and is being degraded while it waits. Whatever follows most plausibly runs through its breakdown to smaller nicotinamide-containing species, which cells then take up and rebuild NAD+ from internally - which is to say, through exactly the precursors people otherwise take directly. This is why every substantial randomised trial in the field used nicotinamide riboside at 255.25 Da or nicotinamide mononucleotide at 334.22 Da rather than the coenzyme itself. The naming inverts the pharmacology: the finished molecule sounds like the most direct option and is the least.

Deep dive: good early evidence, and the gap that keeps getting closed rhetorically

The randomised human literature here is better than for most of this catalogue. NADPARK was a randomised phase I trial of nicotinamide riboside in Parkinson disease in Cell Metabolism. Orr and colleagues ran a randomised placebo-controlled study in older adults in GeroScience. Yoshino and colleagues published NMN and muscle insulin sensitivity in Science. These are real trials in real journals. What they measured, largely, is whether the intervention does what it is supposed to biologically - and raising a biomarker is not the same as changing an outcome. The step that gets taken rhetorically is from a decline that is real, through a mechanism that is identified, to a benefit that has not been demonstrated. Each link looks small; the chain is not. Nothing in this field approaches the scale of what settled the incretin questions, where TRIUMPH alone enrolled more than 5,800 participants with hard clinical endpoints.

Research applications

▸Cellular NAD+ metabolism and salvage pathway research
▸Sirtuin, PARP and CD38 enzyme activity studies
▸Redox biochemistry and NAD+/NADH ratio measurement
▸Cellular senescence and ageing biology research
▸Mitochondrial function and metabolic assay work
▸Comparative precursor uptake and conversion studies

Handling checklist

✓Verify against CID 5892, 663.4 Da, C21H27N7O14P2 - not by sequence
✓Do not apply peptide purity or net peptide content logic - neither exists here
✓Store lyophilised, cold, dry and protected from light
✓Prepare solutions fresh; nucleotide bonds hydrolyse readily in water
✓Be aware NAD+ and NADH are separately quantifiable oxidation states
✓Identity is confirmed by mass and chromatography against a reference standard

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Applying peptide handling and purity guidance to NAD+

Fix: It is a dinucleotide with no peptide bonds. Sequence verification, protease concerns, disulfide chemistry and net peptide content are all inapplicable.

✗ Assuming administered NAD+ enters cells intact

Fix: Two negative phosphate charges and 663 Da prevent membrane crossing, and CD38 degrades it extracellularly. Effects most plausibly run through breakdown products.

✗ Reading precursor trial results as evidence for NAD+ itself

Fix: Every substantial randomised trial used NR or NMN. NAD+ has essentially no comparable human literature.

✗ Treating a biomarker increase as a demonstrated benefit

Fix: Raising NAD+-related markers is reasonably supported. Durable clinical outcome data does not exist.

✗ Taking a precursor's food supplement status as evidence of efficacy

Fix: Supplement frameworks assess safety for consumption, not efficacy, and permit no therapeutic claims.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

What is the difference between NR and NMN?: NR is one step further back in the pathway. Cells phosphorylate NR to NMN, then convert NMN to NAD+.
Which has more trial data?: NR, including NADPARK in Cell Metabolism 2022 and a placebo-controlled study in older adults in GeroScience 2024. NMN's highest-profile result is Yoshino 2021 in Science.
Why not just supply NAD+?: It is over twice NR's mass, carries two negative charges, and does not cross membranes. Precursors do.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More NAD+ articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum